Wells says near-term TrumpRx monetization unlikely material for GoodRx

Wells Fargo notes that GoodRx (GDRX) processes 31 of 43 listed drugs on the newly-launched TrumpRx site, all of which are related to Pfizer (PFE). Web traffic to TrumpRx is growing but is nascent, or roughly 2% of traffic to GoodRx.com, suggesting adoption is early and near-term monetization for GoodRx is “unlikely to be material,” added the analyst, who has an Overweight rating and $7 price target on GoodRx shares.